A Phase I Study of BMS-986497 alone or in combination with Azacitidine (Aza) and Azacitidine plus Venetoclax (AZA+VEN) in relapsed or refractory (R/R) AML or MDS
Phase 1 – testing safety in a small group of people
Conditions:
Acute Myeloid Leukemia and Myelodysplastic Syndrome
Sponsor: Bristol-Myers Squibb Services Unlimited Company
trial.available_in:
БГ
Overview
Trial status: Authorised
Who can participate
Age group: 65+ years, 18-64 years
Gender: Female, Male
Target enrollment: 35 participants
БГ